TabletsClinical Overview
Daclatasvir Tablets (60mg) is a direct-acting antiviral on the WHO Model List of Essential Medicines that specifically targets the hepatitis C virus NS5A protein. Inhibits both viral RNA replication and virion assembly. Indicated in combination with sofosbuvir (with or without ribavirin) for the treatment of chronic HCV genotypes 1 and 3.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 60 mg once daily with or without food in combination with sofosbuvir 400 mg once daily for 12 weeks. Adjust dose to 30 mg with strong CYP3A4 inhibitors, or 90 mg with moderate CYP3A4 inducers.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, fatigue, nausea, diarrhea. Rare/Severe: Severe bradycardia with amiodarone, and HBV reactivation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning for HBV reactivation. Contraindicated with strong CYP3A4/P-gp inducers (carbamazepine, rifampin). Always use in combination with sofosbuvir.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.